News Releases Year None20202019 Jun 29, 2020 Immunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis May 14, 2020 Immunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange Agreement Apr 16, 2020 Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Apr 14, 2020 Immunovant Announces Pricing of $121.2 Million Public Offering Mar 30, 2020 Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease Feb 14, 2020 Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019 Feb 10, 2020 Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Jun 29, 2020 Immunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis
May 14, 2020 Immunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange Agreement
Apr 16, 2020 Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Mar 30, 2020 Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease
Feb 14, 2020 Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019
